Press Release
Category Added in a WPeMatico Campaign
-
Waters Launches Industry’s Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
Brings Xevo™ TQ Absolute XR Mass Spectrometer’s industry-leading tandem quadrupole MS sensitivity to clinical applications across women’s health, cancer assessment,…
Read More » -
Cinven and La Caisse to jointly acquire leading specialty MGA platform, Optio
MONTRÉAL and LONDON, July 27, 2026 /PRNewswire/ — International private equity firm, Cinven, together with global investment group, La Caisse (formerly…
Read More » -
From Wrong Answers to Wrong Actions: The New Risk of Agentic AI in Life Sciences
As AI agents move deeper into regulated scientific workflows, AINGENS argues that autonomy must be bound by evidence, traceability, and…
Read More » -
SHARx Says Pharmacy Benefits Have Become a Major Spend Category With No Clear Owner
SHARx says pharmacy benefits have become one of the employer’s largest healthcare spend, yet responsibility remains fragmented across HR, finance,…
Read More » -
Powerfleet Sets First Quarter Fiscal 2027 Conference Call for Monday, August 10, 2026, at 8:30 a.m. ET
WOODCLIFF LAKE, N.J., July 27, 2026 /PRNewswire/ — Powerfleet, Inc. (Nasdaq: AIOT) today announced that it will hold a conference call…
Read More » -
KGK Science Receives Growth Investment Led by Maxim Partners
Investment positions leading North American CRO to expand clinical research and regulatory capabilities. LONDON, ON and CHICAGO, July 27, 2026…
Read More » -
Unisport Appoints Denise Karkos as Global Chief Marketing Officer
Experienced marketing leader to accelerate brand, community and commercial growth across North America and Globally TAUNTON, Mass., July 27, 2026…
Read More » -
Forum Announces Second Quarter 2026 Earnings Release Date and Webcast Details
PALM BEACH, Fla., July 27, 2026 /PRNewswire/ — Forum Markets, Incorporated (Nasdaq: FRMM), a digital asset platform focused on broadening…
Read More » -
Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter…
Read More » -
Leidos demonstrates tactical cyber detection capability during Valiant Shield 2026
RESTON, Va., July 27, 2026 /PRNewswire/ — Leidos (NYSE: LDOS) successfully demonstrated a tactical cyber detection capability during Valiant Shield 2026,…
Read More »